← All companies
Manufacturing & other
Rhelion Life Sciences
CSE: RHEL · formerly Red Light Holland · Canada
Listed outside the U.S. See the CSE: RHEL quote ↗
Why we cover it
Formerly Red Light Holland. Merged with Filament Health in April 2026; Filament's natural psilocybin drug, PEX010, supplies compassionate-use programs in Germany and a proposed one in Belgium.
Financials
Recent financials aren't available in a standard format for this company. See its listing ↗
Clinical trials Trials tracker
| Trial | Compound | Stage |
|---|---|---|
| PEX010 for Alcohol and Opioid Use Disorder | Psilocybin | Phase 2 |
| PEX010 Compassionate Use for Treatment-Resistant Depression | Psilocybin | Compassionate use (Germany); awaiting approval (Belgium) |
News (1)
In the Journal (4)
- Sep 29, 2026 Only 3 of 10 Psychedelic Companies Lobby Washington. One Just Joined — Twice, in the Same Quarter.
- Sep 23, 2026 Which Psychedelic-Company CEO's Pay Actually Matched Their Stock's Performance? We Checked All 10 — Almost None Did.
- Sep 17, 2026 The Psychedelic Money Graveyard: Renames, Reverse Mergers, and the Companies That Didn't Make It
- Sep 11, 2026 The Psychedelic Money Rankings: $11 Billion Public, $1.6 Billion Private, $140 Million From Governments
Prices are end-of-day closes from Nasdaq; financials come from SEC filings. Not investment advice.